(BPT) - People with narcolepsy may be unaware that their chronic condition may increase their odds of having a stroke , heart disease†, hypertension†, diabetes†, and other …
$7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400 patients initiating therapy as of September 30 LUMRYZ to be added to preferred position for CVS commercial formularies effective January 1, 2024 Submitted sNDA for LUMRYZ in pediatric narcolepsy population on November 7th Management to host a conference call today at 8:30 a.m. ET DUBLI
~ PEDMARK® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October.